Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned a $21.00 price target by Barclays PLC in a research report issued on Wednesday. The firm presently has an “equal weight” rating on the stock. Barclays PLC’s target price points to a potential upside of 33.93% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Mizuho upgraded Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $25.00 to $30.00 in a report on Thursday, June 15th. Royal Bank Of Canada set a $38.00 price objective on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Friday, June 16th. Oppenheimer Holdings, Inc. set a $41.00 price objective on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Tuesday, June 27th. BidaskClub upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a report on Wednesday, July 5th. Finally, Vetr upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $32.27 price objective for the company in a report on Tuesday, July 11th. Five research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $28.72.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 2.49% during mid-day trading on Wednesday, reaching $15.68. The company had a trading volume of 37,585,420 shares. Teva Pharmaceutical Industries Limited has a 12-month low of $15.22 and a 12-month high of $45.85. The stock has a 50 day moving average price of $16.94 and a 200-day moving average price of $26.89. The stock’s market capitalization is $15.93 billion. Teva Pharmaceutical Industries Limited also was the target of unusually large options trading on Wednesday. Investors acquired 29,656 put options on the company. This represents an increase of 231% compared to the typical daily volume of 8,957 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the prior year, the company earned $1.25 earnings per share. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% compared to the same quarter last year. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.28 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Barclays PLC Analysts Give Teva Pharmaceutical Industries Limited (TEVA) a $21.00 Price Target” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/04/teva-pharmaceutical-industries-limited-teva-price-target-lowered-to-21-00-at-barclays-plc.html.

Hedge funds have recently bought and sold shares of the stock. KBC Group NV increased its holdings in shares of Teva Pharmaceutical Industries Limited by 22.7% in the 1st quarter. KBC Group NV now owns 50,684 shares of the company’s stock worth $1,627,000 after purchasing an additional 9,360 shares in the last quarter. American International Group Inc. bought a new stake in shares of Teva Pharmaceutical Industries Limited in the 1st quarter worth $523,000. Cornerstone Capital Management Holdings LLC. bought a new stake in shares of Teva Pharmaceutical Industries Limited in the 1st quarter worth $596,000. Alliancebernstein L.P. increased its holdings in shares of Teva Pharmaceutical Industries Limited by 7.3% in the 1st quarter. Alliancebernstein L.P. now owns 8,617,143 shares of the company’s stock worth $276,524,000 after purchasing an additional 587,286 shares in the last quarter. Finally, Oarsman Capital Inc. increased its holdings in shares of Teva Pharmaceutical Industries Limited by 40.1% in the 1st quarter. Oarsman Capital Inc. now owns 54,460 shares of the company’s stock worth $1,748,000 after purchasing an additional 15,588 shares in the last quarter. 56.77% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.